January 22 – Year-end report 2024
Alligator hosted a webinar on Wednesday, January 22, at 3 p.m. CET for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus presented and commented on the Year-end report, which was followed by a Q&A session.
The call was held in English and can be requested through the link below.
LATEST NEWS
Alligator Bioscience announces leadership transition in clinical development
Lund, Sweden – 21 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chi …
Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer
Lund, Sweden – 20 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Admini …
Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab
Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline da …